Literature DB >> 34780090

Short-term mechanical circulatory support in elderly patients.

Marta Alonso-Fernandez-Gatta1, Soraya Merchan-Gomez1, Ines Toranzo-Nieto1, Miryam Gonzalez-Cebrian1, Alejandro Diego-Nieto1, Alfredo Barrio1, Francisco Martin-Herrero1,2, Pedro L Sanchez1,2.   

Abstract

BACKGROUND: Age over 70 years seems to confer poor prognosis for patients under mechanical circulatory support (MCS). Advanced age is usually a relative contraindication. Our objective was to assess the impact of age on survival of patients with short-term MCS.
METHODS: Retrospective analysis of ≥70-year-old patients supported with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or Impella CP® due to cardiogenic shock and other situations of hemodynamic instability in a referral hospital (elderly group), compared with younger patients (<70 years). We analyze factors associated with survival in elderly group.
RESULTS: Out of 164 short-term MCS implants from 2013 to October 2020, 45 (27.4%) correspond to ≥70-year-old patients (73.3% VA-ECMO; 26.7% Impella CP®), 80% as bridge to recovery and 15.6% for high-risk percutaneous coronary intervention (PCI). We found no significant differences in complications developed between both groups. Survivals at discharge (40% vs. 43.7%, p = 0.403) and at follow-up (median 13.6 [30] months) were similar in elderly and young patients (35.6% vs. 37.8%, log-rank p = 0.061). Predictive factors of mortality in elderly patients were peripheral artery disease (p = 0.037), higher lactate (p = 0.003) and creatinine (p = 0.035) at implant, longer cardiac arrest (p = 0.003), and worse post-implantation left ventricular ejection fraction (p = 0.003). Patients with indication of MCS for high-risk PCI had higher survival compared to other indications (p = 0.013).
CONCLUSION: Short-term MCS with VA-ECMO or Impella CP® in elderly patients may be a reasonable option in hemodynamic compromise situations as bridge to recovery or elective high-risk PCI, without a significant increase in complications or mortality. Age should not be an absolute contraindication, but careful selection of candidate patients is necessary.
© 2021 International Center for Artificial Organs and Transplantation and Wiley Periodicals LLC.

Entities:  

Keywords:  VA-ECMO; cardiogenic shock; elderly; impella; mechanical circulatory support

Mesh:

Year:  2021        PMID: 34780090     DOI: 10.1111/aor.14117

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  5 in total

Review 1.  Impella to Treat Acute Myocardial Infarct-Related Cardiogenic Shock.

Authors:  Jacob Eifer Møller; Jesper Kjaergaard; Christian Juhl Terkelsen; Christian Hassager
Journal:  J Clin Med       Date:  2022-04-26       Impact factor: 4.964

2.  ECMO Predictors of Mortality: A 10-Year Referral Centre Experience.

Authors:  Benedikt Treml; Robert Breitkopf; Zoran Bukumirić; Mirjam Bachler; Johannes Boesch; Sasa Rajsic
Journal:  J Clin Med       Date:  2022-02-24       Impact factor: 4.241

3.  Extracorporeal membrane oxygenation for cardiogenic shock: a meta-analysis of mortality and complications.

Authors:  Sasa Rajsic; Benedikt Treml; Dragana Jadzic; Robert Breitkopf; Christoph Oberleitner; Marina Popovic Krneta; Zoran Bukumiric
Journal:  Ann Intensive Care       Date:  2022-10-05       Impact factor: 10.318

4.  Effects and safety of extracorporeal membrane oxygenation in the treatment of patients with ST-segment elevation myocardial infarction and cardiogenic shock: A systematic review and meta-analysis.

Authors:  Shuo Pang; Guangrui Miao; Xiaoyan Zhao
Journal:  Front Cardiovasc Med       Date:  2022-09-27

5.  PRospective REgistry of PAtients in REfractory cardiogenic shock-The PREPARE CardShock registry.

Authors:  Dirk von Lewinski; Lukas Herold; Christian Stoffel; Sascha Pätzold; Friedrich Fruhwald; Siegfried Altmanninger-Sock; Ewald Kolesnik; Markus Wallner; Peter Rainer; Heiko Bugger; Nicolas Verheyen; Ursula Rohrer; Martin Manninger-Wünscher; Daniel Scherr; Dietmar Renz; Ameli Yates; Andreas Zirlik; Gabor G Toth
Journal:  Catheter Cardiovasc Interv       Date:  2022-07-13       Impact factor: 2.585

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.